Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Circulation study

This article was originally published in The Tan Sheet

Executive Summary

The rates of treatment and control of high cholesterol are "far from optimal," especially among individuals at intermediate and high risk for cardiovascular disease, a study published in the Feb. 7 Circulation finds. Roughly half of the individuals at high- and intermediate-risk of CVD had untreated high cholesterol, or dyslipidemia, compared to less than 20% of individuals in the low-risk group. Additionally, "there is evidence of gender and ethnic disparities in both treatment and control," David Goff, MD/PhD, Wake Forest University School of Medicine, et al., state. "Efforts to improve the treatment and control of dyslipidemia and to eliminate disparities...should be considered among our highest national healthcare quality improvement priorities," they conclude. Goff et al. evaluated 6,704 patients from the Multi-Ethnic Study of Atherosclerosis, a cohort study of individuals between 45-84 years old who were free of clinical CVD at baseline (2000-2002)...

You may also be interested in...



Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

Win For Axonics As England’s NICE Says Rechargeable Neuromodulation Is Cost-Effective

Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.

Topics

UsernamePublicRestriction

Register

PS099087

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel